鹭燕医药(002788) - 2017 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2017 was CNY 1,621,661,503.69, an increase of 1.13% compared to CNY 1,603,511,779.43 in the same period last year[8] - Net profit attributable to shareholders was CNY 23,207,455.33, representing a growth of 6.98% from CNY 21,693,847.48 year-on-year[8] - Net profit excluding non-recurring items was CNY 22,610,167.46, up 4.19% from CNY 21,701,493.97 in the previous year[8] - The expected net profit for the first half of 2017 is projected to be between RMB 54.46 million and RMB 65.35 million, representing a growth of 0% to 20% compared to the same period in 2016[22] Cash Flow and Assets - The net cash flow from operating activities improved significantly to -CNY 160,279,665.96, a 73.38% reduction in cash outflow compared to -CNY 602,181,694.27 in the same period last year[8] - Total assets at the end of the reporting period reached CNY 3,694,538,658.21, a 5.21% increase from CNY 3,511,458,254.02 at the end of the previous year[8] - Net assets attributable to shareholders increased to CNY 1,393,248,697.27, reflecting a growth of 1.68% from CNY 1,370,189,923.35[8] - Accounts receivable at the end of the period decreased by 75.89% to RMB 200,000 due to less settlement with notes[15] - Construction in progress decreased by 40.52% to RMB 45.8561 million as the project was transferred to fixed assets[15] - Other current assets decreased by 37.55% to RMB 17.0809 million due to the deduction of input tax[15] - Prepayments increased by 489.68% to RMB 2.9502 million, indicating an increase in advance payments received[15] Earnings and Returns - Basic earnings per share decreased by 10.00% to CNY 0.18 from CNY 0.20 in the previous year[8] - Diluted earnings per share also fell by 10.00% to CNY 0.18 compared to CNY 0.20 last year[8] - The weighted average return on equity decreased to 1.68%, down 0.66% from 2.34% in the same period last year[8] Non-Recurring Items and Other Income - The company reported non-recurring gains and losses totaling CNY 597,287.87 during the reporting period[9] - Non-operating income increased by 1616.85% year-on-year, primarily from a government subsidy of RMB 1 million received during the period[16] - Financial expenses decreased by 30.18% year-on-year due to reduced bank loans following the IPO[15] - Asset impairment losses increased by 36.95% year-on-year, mainly due to an increase in bad debt provisions[16] Acquisitions and Investments - The company acquired 51% of Sichuan Shibo Pharmaceutical Co., Ltd. for RMB 102 million, becoming its controlling shareholder[19] Operating Performance - Operating cash flow increased by 73.38% year-on-year, attributed to a new procurement policy reducing payment collection time from 60 days to 30 days[16]